PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular, a leader in membrane protein technologies, has initiated a therapeutic target discovery program in immuno-oncology by exploiting its Membrane Proteome Array technology to identify cell-surface proteins involved in regulating the ability of the human immune system to recognize and destroy cancer.
The Membrane Proteome Array is a cell-based screening platform composed of 5,300 unique membrane proteins expressed in live human cells. Using this technology, the company has identified entirely novel immuno-oncology protein interactions, as well as validated therapeutic axes such as PD1/PD-L1. The Membrane Proteome Array is ideally suited to the discovery of new therapeutic targets because each membrane protein is expressed in its functional form on the surface of live human cells, enabling signaling and binding assays to detect functional interactions. In addition, the 5,300 membrane proteins that form the platform represent the largest library of its kind, including over 95% of all known IgV-set proteins and GPCRs.
“No other platform has systematically explored the role of GPCRs, ion channels, and transporters in the immuno-oncology space,” says Benjamin Doranz, CEO of Integral Molecular, adding that “our capabilities in this area have already resulted in the discovery of new immune protein interactions, and we expect to identify more with our novel approach”.
About Integral Molecular
Integral Molecular is a research-driven biotechnology company creating a pipeline of therapeutic antibodies against under-exploited membrane protein targets, including GPCRs, ion channels, transporters, and viral envelope proteins, using its proprietary MPS Discovery Engine®. This platform is built on the company’s Lipoparticle and Shotgun Mutagenesis technologies and over 15 years of experience optimizing membrane proteins, enabling the isolation, characterization, and engineering of monoclonal antibodies against otherwise intractable membrane protein targets. Integral Molecular discovers antibodies for partners in parallel with its own independent work developing antibodies for licensing. The company currently has therapeutic programs focused on pain, metabolic diseases, and viral pathogens.